TG Therapeutics shares are trading higher after TD Cowen initiated coverage on the stock with a Buy rating and announced a price target of $50.
Portfolio Pulse from Benzinga Newsdesk
TG Therapeutics shares rose following TD Cowen's initiation of coverage with a Buy rating and a $50 price target.
October 29, 2024 | 1:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TG Therapeutics shares increased after TD Cowen initiated coverage with a Buy rating and set a price target of $50.
The initiation of coverage by TD Cowen with a Buy rating and a $50 price target is a positive signal for investors, likely leading to increased buying interest and a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100